Intravesical doxorubicin hydrochloride in the prevention of recurrent superficial bladder tumours

Forty patients with Ta-T1 transitional cell carcinoma of the bladder were r and omized to undergo TUR along or TUR combined with intravesical instillation of doxorubicin hydrochloride. Follow-up ranged from 11 to 36 months. There was a significant reduction in the recurrence rate and a significant increase in the disease free interval in the doxorubicin group. The treatment was well tolerated and the reactions to the drug were limited to chemical cystitis and transient hematuria